

# Cellular Therapy Competitive Landscape is Large and Dynamic

... and yet SUPLEXA therapeutic cells stand out as highly differentiated

Feature	SUPLEXA Cells	Tumor Infiltrating Lymphocytes (1 <sup>st</sup> Gen)	CAR-T cells (1 <sup>st</sup> gen)	CAR-T cells (2 <sup>nd</sup> gen)	CAR-macrophages	NK	CAR-NK	γδ T cells	CAR-γδ T cells
Stage of Development	Phase 1 - ready	Late-Stage Clinical	<b>Commercial</b>	Early-Stage Clinical	Pre-clinical	Late-Stage Clinical	Late-Stage Clinical	Early-Stage Clinical	Early-Stage Clinical
Source	Individualized (autologous)	individualized	individualized	off-the shelf (allogeneic)	individualized	Individualized or off-the-shelf	Individualized or off-the-shelf	Individualized or off-the-shelf	Individualized or off-the-shelf
Starting Material	<b>Whole Blood</b>	<b>Patient Tumor</b>	<b>Leukopheresis Procedure</b>	<b>Leukopheresis Procedure</b>	<b>Leukopheresis Procedure</b>	<b>Whole Blood</b>	<b>Leukopheresis Procedure</b>	<b>Whole Blood</b>	<b>Leukopheresis Procedure</b>
Spectrum of Anti-Tumor Activity	<b>Broad</b>	not applicable	<b>Narrow</b>	<b>Narrow</b>	<b>Narrow</b>	<b>Broad</b>	<b>Narrow</b>	<b>Broad</b>	<b>Narrow</b>
Cell type(s)	<b>Multiple</b> <ul style="list-style-type: none"> <li>• NK cell</li> <li>• <b>NKT cell</b></li> <li>• γδ T cell</li> <li>• CD8+ T cell</li> <li>• CD4+ cell</li> </ul>	<b>Single</b> <ul style="list-style-type: none"> <li>• CD8+ T cells (mostly)</li> </ul>	<b>Single</b> <ul style="list-style-type: none"> <li>• CD8+ T cells (mostly)</li> </ul>	<b>Single</b> <ul style="list-style-type: none"> <li>• CD8+ T cells (mostly)</li> </ul>	<b>Single</b> <ul style="list-style-type: none"> <li>• macrophages</li> </ul>	<b>Single</b> <ul style="list-style-type: none"> <li>• NK cell</li> </ul>	<b>Single</b> <ul style="list-style-type: none"> <li>• NK cell</li> </ul>	<b>Single</b> <ul style="list-style-type: none"> <li>• γδ T cells</li> </ul>	<b>Single</b> <ul style="list-style-type: none"> <li>• γδ T cells</li> </ul>
Engineering Required	<b>No</b>	<b>No</b>	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>	<b>No</b>	<b>Yes</b>	<b>No</b>	<b>Yes</b>
Manufacturing/ Cost	<b>Simple/ Inexpensive</b>	<b>Complex/ Expensive</b>	<b>Complex/ Expensive</b>	<b>Complex/ Expensive</b>	<b>Complex/ Expensive</b>	<b>Simple/ Inexpensive</b>	<b>Complex/ Expensive</b>	Simple/ Inexpensive	<b>Complex/ Expensive</b>
Number of Doses	<b>Multiple</b>	TBD	<b>Single</b>	TBD	TBD	TBD	TBD	TBD	TBD
Preconditioning	TBD	TBD	<b>Yes</b>	TBD	TBD	TBD	TBD	TBD	TBD

**Chimeric Antigen Receptors (CAR)** – receptors designed to recognize a specific tumor antigen

